NTRA regulatory decision: FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection AssayNatera, Inc.（NTRA）披露重大监管决定

Barclays raises NTRA target to $475 from $340Barclays 上调目标价 NTRA：$340 → $475

Rating Change · October 7, 2026评级变动 · 2026/10/7

Natera, Inc. (NTRA) falls 6.02% to $400.00Natera, Inc.（NTRA）下跌 6.02%，报 $400.00

Stock Price Move · October 6, 2026个股行情异动 · 2026/10/6

Guggenheim raises NTRA target to $475 from $360Guggenheim 上调目标价 NTRA：$360 → $475

Rating Change · October 1, 2026评级变动 · 2026/10/1